ReviewJournal of immunology (Baltimore, Md. : 1950)2022
Sweet Immune Checkpoint Targets to Enhance T Cell Therapy.
Review in Journal of immunology (Baltimore, Md. : 1950), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 25 citations in OpenAlex.
- β-Mannosyl Triazoles as Mimics of Galactosyl Galectin-3 and Galectin-9 N-Terminal Domain Inhibitors.Chembiochem : a European journal of chemical biology · 2026Article
- Sialic acids modulate immune responses in cancer: Therapeutic opportunities.The Journal of biological chemistry · 2026Review
- A predictive model for immunotherapy efficacy in cancer based on dynamic changes of CD8+ T cells: a pan-cancer retrospective study.Frontiers in immunology · 2026Article
- Single-cell sequencing of peripheral blood mononuclear cells reveals immune landscape of monkeypox patients with HIV.Emerging microbes & infections · 2025Article
- The relationship between galectin-1 expression and the efficacy of anti-PD-1 therapy for non-small cell lung cancer patients.Scientific reports · 2025Article
- Development of Galectin-7-Specific Nanobodies: Implications for Immunotherapy and Molecular Imaging in Cancer.Journal of medicinal chemistry · 2025Article
- The sweet and the bitter sides of galectin-1 in immunity: its role in immune cell functions, apoptosis, and immunotherapies for cancer with a focus on T cells.Seminars in immunopathology · 2025Review
- Advances in nucleic acid-based cancer vaccines.Journal of biomedical science · 2025Review
- Tumor-associated Tn and STn antigens: from molecular mechanism to precision diagnosis and treatment.Frontiers in immunology · 2025Review
- N-Acetylgalactosamine-4-sulfatase (Arylsulfatase B) Regulates PD-L1 Expression in Melanoma by an HDAC3-Mediated Epigenetic Mechanism.International journal of molecular sciences · 2024Article
- Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.Cancer medicine · 2024Article
- The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation.The Journal of biological chemistry · 2024Article
- Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis.Frontiers in immunology · 2024Review
- A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9).Genes & diseases · 2023Review
- KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells.Journal for immunotherapy of cancer · 2023Article
- Review
- Targeting intracellular galectins for cancer treatment.Frontiers in immunology · 2023Review
- Antibody-mediated depletion of programmed death 1-positive (PD-1Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Chimeric Oncolytic Adenovirus Armed Chemokine Rantes for Treatment of Breast Cancer.Bioengineering (Basel, Switzerland) · 2022Article
- Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Despite tremendous success against hematological malignancies, the performance of chimeric Ag receptor T cells against solid tumors remains poor. In such settings, the lack of success of this groundbreaking immunotherapy is in part mediated by ligand engagement of immune checkpoint molecules on the surface of T cells in the tumor microenvironment. Although CTLA-4 and programmed death-1 (PD-1) are well-established checkpoints that inhibit T cell activity, the engagement of glycans and glycan-binding proteins are a growing area of interest due to their immunomodulatory effects. This review discusses exemplary strategies to neutralize checkpoint molecules through an in-depth overview of genetic engineering approaches aimed at overcoming the inhibitory programmed death ligand-1 (PD-L1)/PD-1 axis in T cell therapies and summarizes current knowledge on glycoimmune interactions that mediate T cell immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.